Core Viewpoint - The 2025 "Zhu Liangyi Analytical Instrument Innovation Award" shortlist has been announced, with a public notice period from August 8 to August 22, allowing for public scrutiny and objections regarding the nominated projects [1][3][4]. Summary by Sections Announcement and Public Notice - The award nomination process took place from January 1 to June 30, 2025, with a formal review leading to the shortlist announcement [3]. - The public notice period is set for August 8 to August 22, 2025, during which any concerns regarding the legitimacy of the nominations can be raised [4]. Contact Information - Contact person for inquiries is Liu, with a phone number of 13401022872 and an email address provided for further communication [5]. Shortlisted Projects Innovation Award Nominees - Notable entries include: - Quantum Technology (Hefei) Co., Ltd. with a dual-beam electron microscope [6]. - Harbin Institute of Technology with a droplet electrospray mass spectrometry system [6]. - Nanjing University with a high temporal resolution weak current measurement instrument [6]. Young Innovator Award Nominees - Key submissions include: - Chen Anqi from Ningbo University with a single-cell metabolite analysis mass spectrometer [7]. - Han Shengli from Xi'an Jiaotong University with a high-throughput intelligent CMC · 2D/TDM analyzer [7]. - Li Yingrui from Northwestern Polytechnical University with a line array CdZnTe photon counting detector [7]. Application Innovation Award Nominees - Significant projects include: - Chen Bo from Tongji University with an in-situ scanning electron microscope revealing lithium metal anode fatigue failure mechanisms [8]. - Qiao Zhixian from the Chinese Academy of Sciences with ultra-micro, high-sensitivity genome detection research based on domestic sequencing instruments [8]. - Wang Qingsong from the University of Science and Technology of China with lithium-ion battery thermal runaway fire testing technology [8]. Award Announcement - The results of the 2025 "Zhu Liangyi Analytical Instrument Innovation Award" will be officially announced during the 10th China Analytical Instrument Academic Conference (ACAIC 2025) [8].

Core Viewpoint - Waters Corporation reported strong Q2 performance with revenue reaching $771 million, a year-over-year increase of 8.9%, and a sequential increase of 16.6%. The company also announced a transformative acquisition plan for BD, expecting significant value creation through cost and revenue synergies [4][6][16]. Financial Performance - In Q2, Waters' revenue was $771 million (approximately RMB 5.56 billion), with a year-over-year growth of 8.9% and a sequential growth of 16.6%. The growth was primarily driven by the instrument business, which saw a 4% increase at constant currency, with high single-digit growth in liquid chromatography (LC) and mass spectrometry (MS) [6][7]. - The recurring revenue also grew by 11% at constant currency, reflecting strong demand for high-end analytical instruments, particularly in the Chinese biopharmaceutical sector [10][12]. Regional and Segment Performance - Waters experienced significant growth across different regions, with Asia achieving a 14% increase, Europe growing by 8%, and the Americas only increasing by 2% due to a 20% decline in the TA segment [8]. - Notably, the Chinese market showed remarkable performance with revenue of $117 million, a year-over-year increase of 17% and a sequential increase of 28.9%, driven by strong demand for instrument replacements in quality control and new drug development [10][12]. Strategic Initiatives - The company attributed its strong performance to successful execution of business strategies, innovative product launches, and targeted growth plans. The Alliance iS system saw a threefold increase in sales year-over-year, while other innovations like Xevo TQ Absolute+XR and MaxPeak Premier also experienced significant sales growth [15][16]. - Waters announced the acquisition of BD Biosciences & Diagnostic Solutions, positioning it as a transformative move expected to generate $200 million in cost synergies by the third year post-acquisition and $290 million in additional sales by the fifth year [16][17]. Market Concerns - Following the acquisition announcement, Waters' stock price fell by 11.5%, indicating market skepticism regarding the high valuation of $17.5 billion for BD's divested business, which corresponds to a 19x EBITDA multiple, above the industry average of 15x [21][24]. - Concerns also arose regarding the potential challenges of integrating BD's business, given the differences in business models and regulatory environments, which could complicate the realization of expected synergies [26][28]. Conclusion - Waters' Q2 performance reflects robust operational capabilities and a solid foundation for future growth. However, the market's skepticism regarding the integration of BD's business and the realization of synergies poses a significant challenge for the company moving forward [29].

Core Insights - The report reveals the operational status and future dynamics of the global and Chinese High-Performance Liquid Chromatography (HPLC) market from 2025 to 2031, highlighting the profound impact of U.S. tariff policies on the HPLC industry and its development trends in the coming years [1] Industry Analysis - The report defines HPLC products and analyzes the core aspects of U.S. tariff policies, indicating that adjustments in these policies affect global supply chains and compel Chinese HPLC companies to accelerate their internationalization to address domestic market saturation and global opportunities [1] - The report predicts the global HPLC industry's scale trends over the next few years, considering optimistic, conservative, and pessimistic scenarios, and assesses the direct impacts of tariff policies on Chinese HPLC companies, including rising costs, increased market entry pressures, and supply chain restructuring challenges [1] Market Share and Competition - The report analyzes the market share of major companies in the global HPLC market, providing revenue, sales, and price data for the past three years, indicating a high market concentration where a few leading companies hold a significant portion of the market [3] - It lists the specifications, parameters, and application fields of HPLC products from major global manufacturers and evaluates the competitive landscape of the industry [3] Strategic Recommendations - The report offers several strategic recommendations for companies, including shifting from export dependence to global capacity layout, optimizing supply chain resilience, diversifying markets, innovating products and building technological barriers, compliance risk management, tariff avoidance strategies, and channel transformation and business model innovation [4] - It forecasts the future landscape of the global HPLC industry, particularly China's role in the global market, emphasizing that the HPLC market will be influenced by technological innovation, policy environment, and market demand [4] Capacity and Market Trends - The report predicts the supply and demand status and future trends of the global HPLC market, indicating steady growth in global HPLC capacity over the next few years, with major regions' market sizes expected to continue expanding [4] - It analyzes the growth potential of traditional and emerging markets, focusing on regions such as ASEAN, Russia, Eastern Europe, Mexico, Brazil, the Middle East, and North Africa [4] Product Types and Applications - The report provides a segmented analysis of the HPLC market by product types such as UVS, FD, RID, ED, and CD, noting their varying market performances, and covers application areas including pharmacies, biotechnology, CROs, academia, and chemical products [4] - It predicts future development trends for each product type and application, supported by detailed data [4] Major Manufacturers - The report lists key manufacturers in the HPLC market, including Agilent, Waters, Shimadzu, Thermo Fisher, PerkinElmer, Hitachi, Jasco, Knauer, Bekman, YoungLin, GBC, and Gilson, detailing their product specifications, market performance, and latest developments [5]

Core Insights - The report analyzes the operational status and future prospects of the global and Chinese High-Performance Liquid Chromatography (HPLC) industry from 2025 to 2031, focusing on the impact of U.S. tariff policies and the urgency for Chinese companies to internationalize due to domestic market saturation and global opportunities [1][3][4]. Group 1: U.S. Tariff Policy and HPLC Industry Impact - The evolution of U.S. tariff policies significantly affects the global HPLC supply chain, creating both challenges and opportunities for companies [4]. - The adjustment of U.S. tariffs imposes cost and market access pressures on Chinese HPLC enterprises, necessitating strategic responses [4][5]. - The urgency for Chinese HPLC companies to internationalize is driven by saturated domestic competition and the potential for global market expansion [4]. Group 2: Industry Impact Assessment - The report outlines three scenarios (optimistic, conservative, and pessimistic) for the future growth trends of the global HPLC industry, projecting significant changes in market size from 2024 to 2031 [4][9]. - The direct impact of tariff policies on Chinese HPLC companies includes increased costs and challenges in supply chain restructuring [4][5]. Group 3: Market Share and Competitive Landscape - The report provides insights into the market share and ranking of major global HPLC companies from 2022 to 2025, highlighting revenue-based rankings and sales figures [4][11]. - It details the sales revenue and market share of leading HPLC manufacturers, indicating competitive dynamics within the industry [4][11]. Group 4: Future Outlook and Strategic Recommendations - The report discusses the long-term trends and strategic recommendations for companies to adapt to the evolving global HPLC landscape, emphasizing the need for innovation and market diversification [5][6]. - It highlights the importance of building resilient supply chains and exploring emerging markets to enhance competitive positioning [5][6].

Core Viewpoint - Suzhou Langsheng Scientific Instrument Co., Ltd. has emerged as a significant player in the field of spectroscopic instruments through technological innovation, starting with handheld X-ray fluorescence spectrometers and expanding into various portable analytical instruments widely used in environmental protection, petrochemicals, and scientific research, thereby promoting the development of domestic scientific instruments [2][5]. Group 1: Company Development - Founded in 2012, Langsheng initially targeted the market with handheld X-ray fluorescence spectrometers (XRF) amidst a landscape dominated by international giants [5]. - The company adopted a "low-key and pragmatic" craftsmanship spirit, focusing on breakthroughs in specific scenarios due to the technological gap in core algorithms and detectors in domestic instruments [5]. - In 2014, Langsheng developed the Super-FP algorithm, enhancing the precision of XRF quantitative analysis with advanced mathematical models [5]. - The year 2018 marked the launch of a portable oil analysis instrument that quickly and accurately detects sulfur content in oil, gaining widespread recognition in the maritime system [5][6]. Group 2: Technological Innovations - In 2021, Langsheng introduced the first domestic portable X-ray diffraction instrument, "YingSHINE," filling a gap in the domestic market and enhancing its technical advantages in X-ray crystallography [6]. - The company is set to launch the first domestic portable total reflection X-ray fluorescence spectrometer (TXRF) in 2024, marking a significant breakthrough in trace element analysis technology [6]. - Over the years, Langsheng has developed multiple products, including portable X-ray fluorescence-Raman combined instruments and desktop X-ray diffraction instruments, which have received nominations for industry awards, reflecting their trust and recognition in the scientific instrument sector [6][13]. Group 3: Strategic Transition - Langsheng is transitioning from a device manufacturer to a multi-technology platform solution provider, driven by continuous technological investment and team expansion, with the team size exceeding 100 by 2025 [13]. - The company has adopted a differentiated path of "scene-defined technology" rather than merely pursuing parameter replacement, focusing on specific application areas such as metal materials, environmental protection, and petrochemicals [14]. - Langsheng's technological achievements have been deeply integrated into environmental law enforcement, industrial quality control, and scientific innovation, continuously driving improvements in detection efficiency [14].

Core Viewpoint - The merger between BD and Waters aims to create a new leader in the life sciences and diagnostics sector, targeting the expanding precision medicine and biopharmaceutical markets with a total transaction value of approximately $17.5 billion [1][4][17]. Recent Developments and Future Outlook - In February 2025, BD announced plans to divest its biosciences and diagnostics business, followed by the merger agreement with Waters on July 14, 2025, with completion expected by the end of Q1 2026, pending regulatory approval [3]. - The global life sciences instrument market is projected to reach $85 billion by 2030, with a CAGR of approximately 5-6%, highlighting significant growth opportunities in precision medicine, biopharmaceuticals, and multiplex diagnostics [3]. Strategic Motives - The transaction reflects a strategic shift for both companies: BD focuses on core medical technologies, while Waters seeks to transform its business model from single instrument sales to recurring revenue in diagnostics and services [4][5]. - BD's divestiture aligns with its strategy to concentrate resources on core products like syringes and smart medical devices, which are closely tied to hospital workflows [4][7]. Industry Landscape and Market Opportunities - The merger occurs in a competitive environment where major players like Thermo Fisher and Danaher have expanded through acquisitions, creating pressure on mid-sized analytical instrument companies [5]. - The new company is expected to leverage BD's established presence in Asia, particularly in China and Japan, to enhance global expansion potential [3]. Technical Complementarity - The merger is significant for its technical complementarity, enabling a full chain capability from molecular analysis to cellular detection, which is crucial for biopharmaceutical development and personalized medicine [9][10]. Synergies and Collaborative Value - BD and Waters anticipate achieving approximately $200 million in cost synergies and $290 million in revenue synergies post-merger, but the focus is on the broader industry collaborative value rather than just financial metrics [11]. - The integration of technologies and market strategies is expected to enhance their competitive edge in the life sciences sector [12][16]. Product and Service Integration - The combined entity will offer a comprehensive solution that integrates molecular diagnostics and analytical capabilities, addressing the full spectrum of biopharmaceutical research and clinical validation needs [15]. - The merger allows for the development of complex multiplex testing products, enhancing diagnostic speed and accuracy [15]. Conclusion - The merger between BD and Waters represents a transformative move in the life sciences and diagnostics industry, positioning the new company as a key player in advancing precision medicine and biopharmaceutical innovation [17].

Industry Overview - The global capillary electrophoresis (CE) industry is in a critical phase of technological deepening and application expansion, driven by the growing demand for high-precision analysis in biomedicine, environmental monitoring, and food safety [1][10] - The global CE market is projected to reach $250 million in 2024 and approximately $400 million by 2030, with the life sciences sector being the core growth engine [1][10] - The demand for CE instruments is significantly influenced by the explosive growth in gene sequencing and proteomics research, as well as stringent quality control requirements in the biopharmaceutical industry [1][10] Industry Development History - The CE industry in China has undergone four main stages: inception (1981-1989), domestic exploration (1990-1999), rapid development (2000-2010), and internationalization (2010-present) [4][5][6] - The introduction of commercial CE instruments in 1989 marked the beginning of the technology's practical application, with domestic institutions initially relying on imported equipment [4] - By 2000, CE applications expanded rapidly in biomedical fields, with domestic companies increasing R&D investments to develop competitive products [5] Industry Current Status - The CE industry is experiencing continuous growth due to increased regulatory scrutiny on water quality and pesticide residues, leading to deeper applications in heavy metal analysis and food additive screening [1][10] - The demand for high-end CE models is rising, particularly in the biopharmaceutical sector, where there are strict requirements for antibody drug purity testing and mRNA vaccine quality control [1][10] Industry Supply Chain - The upstream supply chain includes materials such as elastic quartz capillaries, high molecular polymers, and components like high-voltage power supplies and temperature control systems [8] - The midstream involves the manufacturing of CE instruments, while the downstream applications span life sciences, biomedicine, environmental monitoring, and food safety [8] Key Companies and Competitive Landscape - The industry is characterized by a competitive landscape where international giants dominate the high-end market, while domestic companies are rapidly gaining ground in the mid-to-low-end segments [14] - Companies like Beijing Huayang Limin and Shanghai Tongwei are making significant strides in technology and market penetration, offering products that match international standards at lower prices [14][21] - The domestic market is seeing a shift towards high-performance CE instruments with independent intellectual property rights, breaking the monopoly of foreign brands [21] Industry Development Trends - The CE industry is poised for technological upgrades and smart development, with advancements in nanotechnology and automation expected to enhance separation efficiency and sensitivity [19] - The application fields of CE instruments are diversifying, particularly in biomedicine, environmental monitoring, and food safety, driven by rapid technological advancements and cost reductions [20] - The acceleration of domestic substitution is evident, with local companies responding quickly to market demands and enhancing their competitive edge through innovation and collaboration [21]

Group 1: Market Dynamics and Opportunities - The shift towards domestic alternatives in the instrument industry is driven by increased safety awareness and government policies promoting the acceptance of domestic scientific instruments [2] - The industry is experiencing rapid development, leading to the entry of new competitors; however, the market is highly segmented, making it challenging for new entrants to gain a foothold [2] - The domestic scientific instrument sector is expected to evolve quickly due to the involvement of high-end clients, enhancing the iteration of products and broadening application scenarios [2] Group 2: Competitive Advantages and Strategies - The company has accumulated extensive experience in product variety, application scenarios, and solutions, which helps maintain a competitive edge against foreign leaders [2] - The focus on long-term product refinement and quality improvement is essential for sustaining competitiveness in a technology-intensive industry [2][3] - The company plans to emphasize its core business and implement a premium strategy to develop star products and brands while expanding its marketing network [3] Group 3: Operational Adjustments and Workforce Management - The company experienced a significant reduction in employee numbers last year due to structural adjustments; however, the workforce is now stabilizing [3] - Future hiring will be based on the growth potential of specific business segments, with a focus on maintaining stability and efficiency in operations [3] - Cost management will continue to be refined to enhance efficiency and control expenses [3] Group 4: Localization and Supply Chain Development - The localization rate of core components is difficult to quantify, but larger product volumes tend to have higher localization rates [3] - The development of industry supply chains is crucial, with the need for leading companies to drive growth in the analysis instrument sector, characterized by diverse and small-batch production [3]

Core Viewpoint - The article discusses the naming conventions of analytical instruments as per the standard GB/T12519-2021, emphasizing the importance of adhering to established naming principles to avoid confusion in the industry [1][2]. Group 1: Naming Principles - The naming of analytical instruments is guided by specific principles that consider the measurement method and the object being measured [2]. - Instruments that measure a single substance (excluding gases) and assign values are typically referred to as "meters," such as pH meters and salinity meters [2]. - Instruments designed to measure gases are generally called "analyzers," for example, carbon monoxide analyzers and carbon dioxide analyzers [2]. - Instruments that analyze images to study the morphology of substances are referred to as "microscopes," such as transmission electron microscopes and scanning electron microscopes [2]. - Systems that encompass sample processing, analytical instruments, data management, and auxiliary facilities are usually called "systems," like air quality detection systems and water quality detection systems [2]. - Other analytical instruments not fitting the above categories are generally referred to as "instruments" [2]. - Safety alarm instruments that only provide sound or light warnings are typically called "alarm devices," while those with other display methods are referred to as "explosion detectors" or "detectors" [2].

Core Viewpoint - The beauty industry is currently facing a significant controversy regarding the actual content of recombinant collagen, with a focus on the lack of standardized testing methods and criteria, which has led to a trust gap between brands and consumers [2]. Group 1: Industry Controversy - A beauty blogger reported that the recombinant collagen content in a popular product was only 0.0177%, significantly below the national standard of 0.1%, and failed to detect key amino acids like glycine [2]. - The controversy centers not on the technical routes or raw material sources, but on the choice of testing methods and the absence of unified standards, which has hindered the compliant development of the medical beauty industry [2]. Group 2: Regulatory Developments - Since 2022, the National Medical Products Administration (NMPA) has been releasing industry standards for recombinant collagen, including YY/T 1849-2022 and YY/T 1888-2023, to address the heterogeneity of recombinant collagen products [3]. - The introduction of mass spectrometry as a "gold standard" for quality control in recombinant collagen is expected to replace traditional methods that are susceptible to interference from other proteins [3]. Group 3: New Standards Implementation - On August 1, 2022, the NMPA implemented YY/T 1805.3-2022, which provides a high-specificity method for detecting collagen content using LC-MS/MS, addressing the limitations of traditional methods [4]. - A new standard, YY/T 1954-2025, for peptide fingerprint analysis of recombinant collagen is set to be implemented on March 1, 2026, which will enhance quality control and regulatory capabilities in the medical beauty industry [8]. Group 4: Industry Support and Collaboration - The Instrument Information Network is actively monitoring developments in cosmetic testing and promoting collaboration in the field, emphasizing the importance of advancements in testing technology and equipment [13].